
Loading, please wait...

Loading, please wait...

The SAXOPHONE trial recently highlighted the safety of using apixaban in pediatric heart disease for thromboprophylaxis. Within this primary trial design, researchers included an exploratory substudy to evaluate the drug's impact on surrogate biomarkers of efficacy. Specifically, the medical team monitored changes in d-dimer levels, thrombin generation assay (TGA) parameters, and various hemostatic proteins. By comparing apixaban to standard-of-care treatments like vitamin K antagonists (VKAs) and low-molecular-weight heparin, the study provides valuable insights into pediatric anticoagulation management.
The results showed that d-dimer levels decreased significantly at the six-month mark across all treatment groups. Furthermore, the findings indicated that apixaban in pediatric heart disease significantly prolonged the TGA lag time and the time to peak compared to VKAs. This suggests a potent reduction in hypercoagulability. Although apixaban reduced peak thrombin similarly to VKAs in anticoagulant-naïve patients, it effectively preserved the endogenous thrombin potential. Consequently, these changes align with observations previously recorded in adult populations, supporting the clinical efficacy of this direct oral anticoagulant.
Regarding hemostatic proteins, apixaban decreased fibrinogen and factor VIII levels at six months. However, the drug did not significantly alter protein C or protein S levels. Additionally, prior exposure to VKAs caused noticeable carryover effects, which suppressed baseline d-dimer and other protein levels. Overall, the substudy supports the primary outcomes of the SAXOPHONE trial. It reinforces the favorable risk-benefit profile of apixaban as a convenient and effective option for children requiring long-term anticoagulation. These findings offer clinicians a more predictable alternative to traditional therapies that often require frequent monitoring.
It demonstrates that apixaban successfully reduces markers of hypercoagulability, such as d-dimer, and prolongs thrombin generation lag time in children with heart disease.
According to the trial data, apixaban does not have a significant effect on protein C or protein S levels in pediatric patients with heart disease.
The study indicates that apixaban provides similar reductions in hypercoagulability and peak thrombin as vitamin K antagonists, while offering a more favorable safety and convenience profile.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A substudy of the SAXOPHONE trial reveals how apixaban affects hemostatic biomarkers and thrombin generation in children with heart disease....
4 months ago

Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today

An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back

A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back

Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back

With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today